"Researchers led by metabolism expert Prof Timo D. Müller at Helmholtz Munich have developed a new strategy to treat obesity and type 2 diabetes. Their approach uses a specially designed hybrid molecule that takes advantage of the well-known GLP-1/GIP signalling pathway as a kind of entry point into cells. Once inside, it delivers an additional metabolic compound directly where it is needed."
"In laboratory tests, mice treated with this compound ate less food, lost more weight, and showed better blood-glucose control than those given standard comparison treatments. The findings were published as a preclinical study in the journal Nature."
"One goal is to add drugs that improve how cells respond to insulin, helping glucose move more efficiently from the bloodstream into tissues. The challenge is that many of these additional drugs affect the entire body rather than specific target cells, raising the likelihood of side effects."
Helmholtz Munich researchers created a novel obesity and type 2 diabetes treatment using a hybrid molecule that leverages the GLP-1/GIP signaling pathway as a cellular entry point. This "Trojan horse" approach delivers an additional metabolic compound directly to target cells, avoiding systemic distribution. In preclinical mouse studies, the treatment demonstrated reduced food intake, increased weight loss, and improved blood glucose control compared to standard therapies. The targeted delivery mechanism enables lower drug doses while maintaining efficacy, potentially minimizing side effects associated with current incretin-based treatments that affect the entire body.
#glp-1gip-therapy #obesity-treatment #targeted-drug-delivery #metabolic-enhancement #type-2-diabetes
Read at ScienceDaily
Unable to calculate read time
Collection
[
|
...
]